JP2024531728A - 心血管疾患の処置 - Google Patents
心血管疾患の処置 Download PDFInfo
- Publication number
- JP2024531728A JP2024531728A JP2024516476A JP2024516476A JP2024531728A JP 2024531728 A JP2024531728 A JP 2024531728A JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024516476 A JP2024516476 A JP 2024516476A JP 2024531728 A JP2024531728 A JP 2024531728A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- molecule
- nucleotide sequence
- double
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/312—Phosphonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2113104.0 | 2021-09-14 | ||
| GBGB2113104.0A GB202113104D0 (en) | 2021-09-14 | 2021-09-14 | Antagonist of pcsk9 |
| GB2207239.1 | 2022-05-18 | ||
| GBGB2207239.1A GB202207239D0 (en) | 2022-05-18 | 2022-05-18 | Treatment of cardiovascular disease 2 |
| PCT/EP2022/075355 WO2023041508A2 (en) | 2021-09-14 | 2022-09-13 | Treatment of cardiovascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531728A true JP2024531728A (ja) | 2024-08-29 |
| JP2024531728A5 JP2024531728A5 (cg-RX-API-DMAC7.html) | 2025-07-23 |
Family
ID=83691543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024516476A Pending JP2024531728A (ja) | 2021-09-14 | 2022-09-13 | 心血管疾患の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250283076A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4402263A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531728A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229020A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023041508A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240103025A9 (ko) | 2021-11-16 | 2025-12-10 | 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. | 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법 |
| TW202345865A (zh) * | 2022-01-24 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 抑制LPA(Apo(a))蛋白表達的組合物和方法 |
| EP4680740A1 (en) * | 2023-03-14 | 2026-01-21 | Argonaute Rna Limited | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule |
| AU2024265748A1 (en) * | 2023-05-04 | 2025-10-23 | Argonaute RNA Limited | Dual silencing |
| WO2024245151A1 (zh) * | 2023-05-26 | 2024-12-05 | 维亚臻生物技术(苏州)有限公司 | 一种用于代谢疾病的双链核苷酸化合物及其应用 |
| TW202515586A (zh) * | 2023-08-09 | 2025-04-16 | 大陸商北京福元醫藥股份有限公司 | 抑制DGAT2基因表達的siRNA、siRNA綴合物或其前藥和藥物組合物及用途 |
| CN120035670A (zh) * | 2023-08-23 | 2025-05-23 | 云合智药(苏州)生物科技有限公司 | 用于抑制二酰甘油-O-酰基转移酶2表达的RNAi剂及其应用 |
| TW202540420A (zh) * | 2023-11-15 | 2025-10-16 | 大陸商北京加科瑞康醫藥科技有限公司 | 用於抑制LPA的基因表現的siRNA,含其的組合物及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020099476A1 (en) * | 2018-11-13 | 2020-05-22 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| WO2021001646A2 (en) * | 2019-07-02 | 2021-01-07 | Argonaute RNA Limited | Apolipoprotein b antagonist |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2219517T3 (es) | 2000-03-03 | 2004-12-01 | Glaxosmithkline Biologicals S.A. | Vacuna para el tratamiento de la aterosclerosis. |
| GB0121171D0 (en) | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305794D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| EP1675949A2 (en) | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8067572B2 (en) * | 2005-05-25 | 2011-11-29 | The University Of York | Hybrid interfering RNA |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| CA2658183A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina) |
| WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
| WO2012058693A2 (en) * | 2010-10-29 | 2012-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of pcsk9 genes |
| BR112015013105B1 (pt) * | 2012-12-05 | 2022-02-08 | Alnylam Pharmaceuticals, Inc | Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro |
| PL2992098T3 (pl) | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| EP3656386A1 (en) | 2013-06-21 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile |
| JOP20160211B1 (ar) | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| US11065216B2 (en) | 2016-11-16 | 2021-07-20 | Purdue Research Foundation | Compositions and methods for regulating body weight and metabolic syndromes |
| CN119120476A (zh) | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| JP7827623B2 (ja) * | 2019-12-09 | 2026-03-10 | アムジエン・インコーポレーテツド | LPA発現を阻害するためのRNAiコンストラクト及び方法 |
| US20230183694A1 (en) * | 2020-03-16 | 2023-06-15 | Argonaute RNA Limited | Antagonist of pcsk9 |
-
2022
- 2022-09-13 US US18/691,775 patent/US20250283076A1/en active Pending
- 2022-09-13 CA CA3229020A patent/CA3229020A1/en active Pending
- 2022-09-13 WO PCT/EP2022/075355 patent/WO2023041508A2/en not_active Ceased
- 2022-09-13 EP EP22789482.1A patent/EP4402263A2/en not_active Withdrawn
- 2022-09-13 JP JP2024516476A patent/JP2024531728A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020099476A1 (en) * | 2018-11-13 | 2020-05-22 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of lpa in a cell |
| WO2021001646A2 (en) * | 2019-07-02 | 2021-01-07 | Argonaute RNA Limited | Apolipoprotein b antagonist |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023041508A3 (en) | 2023-06-08 |
| WO2023041508A2 (en) | 2023-03-23 |
| US20250283076A1 (en) | 2025-09-11 |
| CA3229020A1 (en) | 2023-03-23 |
| EP4402263A2 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4402263A2 (en) | Treatment of cardiovascular disease | |
| US20190078088A1 (en) | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | |
| JP2024500035A (ja) | 心血管疾患の治療 | |
| Watts et al. | Clinical status of duplex RNA | |
| GB2631903A (en) | Dual silencing | |
| JP2023545502A (ja) | リポタンパク質(a)を阻害するためのrna組成物および方法 | |
| JP2023519140A (ja) | Pcsk9のアンタゴニスト | |
| JP2021185149A (ja) | アポリポタンパク質(a)発現の調節 | |
| JP2013511964A (ja) | miRNA−100を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| KR20150006743A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| GB2618915A (en) | Treatment of cardiovascular disease | |
| JP2022543136A (ja) | Apoc3関連疾患および障害の処置のための方法 | |
| JP2022537987A (ja) | アポリポタンパク質bアンタゴニスト | |
| CN118103508A (zh) | 心血管疾病的治疗 | |
| JP5406024B2 (ja) | Bcl−XL特異的siNAを用いる癌治療法 | |
| EP4680740A1 (en) | Conjugate comprising a double stranded rna molecule linked to a single stranded dna molecule | |
| GB2629617A (en) | Dual silencing | |
| KR20260006569A (ko) | 이중 발현 억제 | |
| WO2026092544A1 (zh) | 靶向mtarc1基因的寡核苷酸及其用途 | |
| TW202526015A (zh) | 靶向LPA基因的RNAi劑及其用途 | |
| WO2026026890A1 (zh) | 用于抑制LPA基因表达的siRNA及其修饰物与应用 | |
| WO2024222686A1 (zh) | 用于抑制LPA表达的RNAi剂及其应用 | |
| WO2026017176A1 (zh) | 靶向微管相关蛋白Tau基因的寡核苷酸及其用途 | |
| WO2025242147A1 (zh) | 靶向外周髓鞘蛋白-22基因的寡核苷酸及其用途 | |
| WO2026087871A1 (en) | Gene silencing of cardiovascular genes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240621 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250714 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260512 |